Qdenga
Qdenga gained approval for use in Australia through the Therapeutic Goods Administration (TGA) in mid-March 2026 and was registered on 8 April 2026.
Previously, Qdenga was available under the Special Access Scheme (SAS).
Indonesia was the first country in the world to grant approval for Qdenga in August 2022.
Approval quickly followed in the European Union (December 2022), the United Kingdom (February 2023), Brazil and Thailand. Qdenga is currently registered in more than 41 countries (October 2026) with more than 30 million doses of the vaccine distributed globally since it was first made commercially available.
Many travellers have already received the vaccine in Australia under the Special Access Scheme.
Technical advice on the recommended use of the vaccine varies from country to country. The Australian Technical Advisory Group on Immunisation released its advice on 24 September 2026. It is very helpful and quite broad in its application. See: ATAGI statement on the clinical use of the dengue vaccine Qdenga for Australians
The vaccine is now commercially available in Australia (October 2026).
Qdenga is a live attenuated tetravalent vaccine. It is based on a “backbone” of the dengue serotype 2 virus and includes genetic material from all four dengue virus serotypes. More than 60,000 individuals have participated in trials in Latin America and Asia since 2016.
It is recommended from 4 years of age and given in a 2-dose schedule with a 3-month interval between doses. Protection is present from 14 days. The length of protection is yet to be defined but likely more than 4 years. Booster doses have not yet been defined.
A protective efficacy of between 60% and 95% (average 80%) for virologically identified dengue fever at 12 months post second dose and lasting for more than 4.5 years. (The protective efficacy is greater for those who have had a previous dengue fever infection. It also varies according to the serotype of the dengue virus.)
The vaccine has a good safety profile with injection site discomfort (50%), headache (35%), muscle aches and pains (31%), tiredness (24%) and fever (11%) mentioned. These reactions are common to many other vaccinations. Side effects are more likely after the first dose than the second.
The vaccine cannot be given to women who are pregnant or breast feeding. It should also be avoided in those with congenital or acquired immune deficiency. People living with HIV who are not immunocompromised can be given the vaccine (CD4 count assessment).
The product information can be sourced through the TGA website.
Another dengue fever vaccine, Dengvaxia, was previously available in Australia.
Dengvaxia first gained regulatory approval in 2015 (3-dose vaccine, spaced 6 months apart). Regulatory approval was given in several countries for use in dengue endemic countries but restricting its use to the age group 9 to 45 years.
It was offered off-licence in Australia in 2019 and was used in a very limited way ever since. There is no current availability in Australia or New Zealand.
The World Health Organisation (WHO) issued a conditional recommendation in 2016 for Dengvaxia use in highly endemic areas, defined by a seroprevalence of 70% and above.
Analysis of the vaccine in 2017 showed there was an increased risk for vaccinated individuals to develop severe dengue in their first natural dengue infection after vaccination.
In the event of travel to a dengue-endemic or outbreak region, it is advisable to seek medical advice regarding the suitability of the dengue vaccination. This is determined on a case-by-case basis, particularly for individuals who have had dengue in the past.
According to the WHO, individuals aged 17 to 60 travelling from non-endemic countries to high burden areas might benefit from the vaccine if they have had previous dengue. Frequent travellers or long-term expatriates who may have experienced previous asymptomatic dengue might also benefit from vaccination.
Consideration of the vaccine should be discussed with a health professional, as the use of these vaccines is still in its early stages. WHO released a position paper on dengue fever vaccines in 2024. See: WHO position paper on dengue vaccines
Not sure if a dengue vaccine is right for you? A telehealth consult with one of our travel doctors can help you decide. Suitability depends on your destination, length of stay, previous dengue exposure, and overall health. Book a travel health consultation to discuss your options before you travel.